Answer
The common skin and subcutaneous tissue adverse reactions listed for deucravacitinib in plaque psoriasis trials are acneiform rash and folliculitis.
Sources for this answer
- SOTYKTU 6 mg film coated tabletsBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.8 Undesirable effects · Version 3Document updated
Sources checked